ClinicalTrials.gg
Not yet recruitingNCT06716775Updated Dec 4, 2024

Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.

An interventional study of Tumor treating felds (TTF) and Best Standard of Care in NSCLC Brain Metastasis, sponsored by Jiangsu Healthy Life Innovation Medical Technology Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Jiangsu Healthy Life Innovation Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the treatment of brain metastases from non-small cell lung cancer (NSCLC) .

02

Conditions studied

  • NSCLC Brain Metastasis

Browse trials for

Keywords

  • TTF
  • NSCLC brain metastasis
03

In context

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

This study's planned enrollment of 200 is above the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Jiangsu Healthy Life Innovation Medical Technology Co., Ltd is the lead sponsor of 5 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The age of the subject was between 18 and 75 years old (inclusive), regardless of gender;
  2. The predicted survival time was ≥3 months;
  3. Newly diagnosed with NSCLC ;
  4. MRI imaging showed 1-10 unresectable brain metastases;
  5. performance status (KPS) score ≥70;
  6. Able to operate the TTF independently or with the help of a caregiver;
  7. Subjects of had to agree to use effective for the duration of the trial;
  8. Voluntarily signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Positive driver genes;
  2. Recurrent of NSCLC;
  3. Suffering from severe cerebral edema;
  4. ;
  5. Participants had to meet certain criteria for bone marrow, liver and kidney function before enrollment, and were not eligible if they had any of the following:

    1. count \< 100×103/μL;
    2. \< 1.5×103/μL;

    d. or ALT exceeding 2.5 times the ; c.Total more than 1.5 times the upper limit of the normal range; d.Severe renal impairment (serum creatinine >1.7 mg/dL, or >150 μmol/L);

  6. There were infection, ulcer and unhealed wound in the skin where the electrode was applied;
  7. Patients allergic to conductive hydrogels or medical adhesives;
  8. Those who are pregnant or preparing to become pregnant or who are breastfeeding;
  9. Patients with poor compliance, as judged by the investigator, or other factors considered by the investigator to be not suitable for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    TTF+Best Standard of Care

    Device: Tumor treating felds (TTF) · Other: Best Standard of Care

  • Active comparator
    Best Standard of Care

    Other: Best Standard of Care

Interventions

  • DeviceTumor treating felds (TTF)

    Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day.

  • OtherBest Standard of Care

    Patients will be treated with the best known standard of care for NSCLC brain metastasis and undergo SRS alone.

06

What researchers measure

Primary outcomes

  1. Intracranial tumor progression-free survival (iPFS)

    Defined as the time from randomization to the first occurrence of intracranial progression (according to RANO-BM criteria) or neurologic death, whichever occurred first.

    Time frame: 3 years

Secondary outcomes

  1. Overall Survival (OS)

    Defined as the time from the date of treatment until death due to any cause.

    Time frame: 3 years

  2. Objective response rate (ORR)

    Defined as the number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR).

    Time frame: 3 years

  3. Time to neurocognitive failure

    Time frame: 3 years

  4. Rate of intracranial progression at 2, 4, 6, 8, 10, 12 months

    Time frame: 3 years

  5. Neurocognitive failure-free survival

    Time frame: 3 years

  6. Rate of decline in cognitive function

    Time frame: 3 years

  7. Number of participants with adverse events (AEs)

    Adverse events will be defined as the incidence, frequency and severity of adverse events (AEs) noted in patients treated with study treatments

    Time frame: 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Jun 2028, 42 months later.

Of 320 interventional studies with no phase under Neoplasm Metastasis, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 91. This study's planned 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 4, 2024
StartEst.
Dec 20, 2024
Primary completionEst.
Jun 30, 2028
CompletionEst.
Oct 30, 2028
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06716775
Lead sponsor
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Dec 20, 2024 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Dec 4, 2024

Study contacts

Ligang Xing Dr Xing, Doctor
Contact
xinglg@medmail.com.cn
(0531)87984777

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion